---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-21-055255"
form_type: "8-K"
ticker: "ACAD"
cik: "0001070494"
company_name: "ACADIA PHARMACEUTICALS INC"
filed_at: "2021-11-08T23:59:59+00:00"
generated_at: "2026-06-28T11:15:26.157506+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Acadia Pharma Q3 net loss narrows to $0.09/shr; NUPLAZID sales up 9% to $131.6M

## Summary
- Net loss per share of $0.09, improved from $0.54 loss in Q3 2020; revenue $131.6M (+9% YoY).
- 2021 NUPLAZID sales guidance narrowed to $480M-$500M from $480M-$515M; R&D guidance lowered.
- FDA meeting scheduled to discuss pimavanserin sNDA resubmission for dementia-related psychosis subgroups.
- Top-line results expected Q4 2021 for trofinetide (Rett syndrome) and Q1 2022 for ACP-044 (pain).
- Promoted Brendan Teehan to EVP, COO, Head of Commercial; Julie Fisher to SVP, Marketing.

## SEC filing metadata
- accession: 0001564590-21-055255
- form_type: 8-K
- ticker: ACAD
- cik: 0001070494
- company_name: ACADIA PHARMACEUTICALS INC
- filed_at: 2021-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1070494/000156459021055255/0001564590-21-055255-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1070494/000156459021055255/acad-8k_20211108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-21-055255
- JSON: https://secwatch.observer/filing/0001564590-21-055255.json
- Plain text: https://secwatch.observer/filing/0001564590-21-055255.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.